​
​

Nautilus Bio Stock (NASDAQ:NAUT)

ForecastRevenueOwnershipFinancialsChartTranscripts
Nautilus Bio by TradingView

Previous Close

$2.73

52W Range

$2.19 - $4.00

50D Avg

$2.52

200D Avg

$2.70

Market Cap

$363.69M

Avg Vol (3M)

$71.04K

Beta

1.02

Div Yield

-

NAUT Company Profile

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

164

IPO Date

Aug 07, 2020

Website

NAUT Performance

NAUT Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-63.67M$-63.62M$-50.50M
Net Income$-63.67M$-63.74M$-50.31M
EBITDA$-63.67M$-60.20M$-47.66M
Basic EPS-$-0.51$-0.60
Diluted EPS-$-0.51$-0.60

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q2 24Jul 30, 24 | 3:16 PM
Q1 24Apr 30, 24 | 12:00 AM
Q4 23Feb 28, 24 | 1:13 PM

Peer Comparison

TickerCompany
CYTCyteir Therapeutics, Inc.
PMVPPMV Pharmaceuticals, Inc.
KYMRKymera Therapeutics, Inc.
DTILPrecision BioSciences, Inc.
RVMDRevolution Medicines, Inc. Warrant
BCABBioAtla, Inc.
FHTXFoghorn Therapeutics Inc.
IPSCCentury Therapeutics, Inc.
CSBRChampions Oncology, Inc.
CRBUCaribou Biosciences, Inc.
CCCCC4 Therapeutics, Inc.
HCWBHCW Biologics Inc.
MNOVMediciNova, Inc.
RZLTRezolute, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
BEAMBeam Therapeutics Inc.
MOLNMolecular Partners AG
FIXXQ32 Bio Inc.
ELYMEliem Therapeutics, Inc.